RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
The FDA has signed off on emergency use of Royal Philips’ (PHG -0.6%) Intellivue Patient Monitors MX750/MX850 and Intellivue Active Displays AD75/AD85 for remotely monitoring hospitalized COVID-19 patients.
The devices were CE Mark’d last year and are in use in hospitals across Europe.
AgeX Therapeutics (NYSEMKT:AGE) inks a non-binding letter of intent with ImStem Biotechnology to obtain from AgeX, a non-exclusive license to use its embryonic stem cell line ESI 053 to derive ImStem’s investigational MSC product IMS001 for development in COVID-19 as well as acute respiratory distress syndrome (ARDS) due to other causes.
Financial terms and other provisions of agreement are yet to be finalized.
AGE is up 12% premarket.
SmileDirectClub (NASDAQ:SDC) has expanded its SmileShop partnership with Watsons, Asia’s largest health and beauty products retailer, with its first locations in Mong Kok and Kwun Tong in Hong Kong.
Shares up 2% premarket on light volume.
Northwest Biotherapeutics (OTCQB:NWBO +5.2%) announces that the data lock for its Phase 3 clinical trial evaluating DCVax-L in glioblastoma patients may be completed as early as mid-June.
Management says the specific timing of its announcement of results is uncertain at this point.
Moderna (NASDAQ:MRNA) is hosting its third annual Science Day event today during which it will virtually present advances in its platform science and vaccines. Highlights:
T7 RNA polymerase engineered not to produce double-stranded RNA impurities (a technical issue in the production of mRNA therapeutics).
Update on research in delivery science to optimize its lipid nanoparticles, specifically, an engineered lipid that enhances its interactions with mRNA. It will be used with candidate mRNA-3745 for glycogen storage disease type 1a.
Company’s mRNA platform enabling rapid design and clinical testing of HIV-1 vaccine (designed to deliver an engineered HIV immunogen).
Pipeline consists of 23 mRNA candidates. 13 clinical trials in process.
Shares down 1% premarket on light volume.
